Assessing dynamic metabolic heterogeneity in prostate cancer patients via total-body [68Ga]Ga-PSMA-11 PET/CT imaging: quantitative analysis of [68Ga]Ga-PSMA-11 uptake in pathological lesions and normal organs-Reference-Cited by-同舟云学术

Assessing dynamic metabolic heterogeneity in prostate cancer patients via total-body [68Ga]Ga-PSMA-11 PET/CT imaging: quantitative analysis of [68Ga]Ga-PSMA-11 uptake in pathological lesions and normal organs

Published:2023-10-27 Issue:3 Volume:51 Page:896-906
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Chen Ruohua,Ng Yee Ling,Yang Xinlan,Zhu Yinjie,Li Lianghua,Zhao Haitao,Huang Gang^ORCID,Liu Jianjun

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00259-023-06475-y.pdf

Reference37 articles.

1. Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, et al. (18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019;20:1286–94. https://doi.org/10.1016/S1470-2045(19)30415-2.

2. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–95. https://doi.org/10.1007/s00259-012-2298-2.

3. Bertoldo A, Rizzo G, Veronese M. Deriving physiological information from PET images: from SUV to compartmental modelling. Clin Transl Imaging. 2014;2:239–51. https://doi.org/10.1007/s40336-014-0067-x.

4. Dimitrakopoulou-Strauss A, Pan L, Sachpekidis C. Kinetic modeling and parametric imaging with dynamic PET for oncological applications: general considerations, current clinical applications, and future perspectives. Eur J Nucl Med Mol Imaging. 2021;48:21–39. https://doi.org/10.1007/s00259-020-04843-6.

5. Zaidi H, Karakatsanis N. Towards enhanced PET quantification in clinical oncology. Br J Radiol. 2018;91:20170508. https://doi.org/10.1259/bjr.20170508.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long Axial Field-of-View (LAFOV) PET/CT in Prostate Cancer;Seminars in Nuclear Medicine;2024-06

2. Clinical Implementation of Total-Body PET in China;Journal of Nuclear Medicine;2024-05

3. The Role of Total-Body PET in Drug Development and Evaluation: Status and Outlook;Journal of Nuclear Medicine;2024-05

4. Combined whole-body dynamic and static PET/CT with low-dose [18F]PSMA-1007 in prostate cancer patients;European Journal of Nuclear Medicine and Molecular Imaging;2024-01-30